XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.08 | -0.04 | +50.00% | $0 | ✅ Beat | +2.06% | -8.58% | — |
| 2026-03-23 | Q4 2025 | -0.07 | -0.06 | +14.29% | $0 | ✅ Beat | +8.04% | -6.91% | -1.88% |
| 2025-11-12 |
| Q3 2025 |
| -0.12 |
| -0.11 |
| +8.33% |
| $1,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.12 | -0.10 | +16.67% | $0 | ✅ Beat | -1.07% | +13.31% | +118.81% |
| 2025-03-31 | Q4 2024 | -0.16 | -0.07 | +56.25% | $0 | ✅ Beat | +7.07% | +1.41% | -1.01% |
| 2024-11-13 | Q3 2024 | -0.20 | -0.13 | +35.00% | $0 | ✅ Beat | -25.61% | -20.63% | -26.97% |
| 2024-08-14 | Q2 2024 | -0.23 | -0.15 | +34.78% | $0 | ✅ Beat | +1.16% | +5.93% | +4.65% |
| 2024-05-14 | Q1 2024 | -0.22 | -0.16 | +27.27% | $0 | ✅ Beat | +19.12% | +2.94% | -3.92% |
Showing last 8 quarters.